Tolerability, Pharmacokinetics, and Efficacy of MP-101 in the Treatment of Patients With Dementia-Related Psychosis and/or Agitation and Aggression
Latest Information Update: 05 Apr 2021
At a glance
- Drugs MP 101 Mediti Pharma (Primary)
- Indications Alzheimer's disease; Lewy body disease; Parkinson's disease; Vascular dementia
- Focus Therapeutic Use
- Sponsors Mediti Pharma
- 24 Feb 2020 Status changed from active, no longer recruiting to discontinued.
- 14 Feb 2020 Planned End Date changed from 1 Aug 2020 to 1 Feb 2020.
- 14 Feb 2020 Planned primary completion date changed from 1 Aug 2020 to 1 Feb 2020.